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716Haploidentical/Mismatched Hematopoietic Stem Cell
Transplantation without In Vitro T Cell Depletion
for T Cell Acute Lymphoblastic Leukemia
Yu Wang, Dai-Hong Liu, Lan-Ping Xu, Kai-Yan Liu, Huan Chen, Yu-Hong Chen,
Wei Han, Xiao-hui Zhang, Xiao-Jun HuangThe outcome of T cell acute lymphoblastic leukemia (T-ALL) is poorly understood. Allogeneic hematopoietic
stem cell transplantation (HSCT) remains 1 of the best options to cure T-ALL. However, many patients cannot
find an HLA-matched donor. Our institute established a new protocol for haplo-identical HSCT. Busulfan,
cyclophosphamide, cytosine arabinoside, and methyl CCNU plus antithymocyte globulin was used for condi-
tioning therapy. Seventy-two patients diagnosed with T-ALL underwent transplantation from haploidentical
donor family members. The incidence rates of grades II to IV acute graft-versus-host disease (aGVHD) and
of grades III and IV aGVHD were 49% 6 12% and 19% 6 12%, respectively. The cumulative incidence rate
for chronic GVHD (cGVHD) at 2 years after HSCTwas 41%6 12%. After a median follow-up of 12 months,
15 patients had relapsed, 14 died from relapse, and 41 patients were still alivewithout disease recurrence. The
probability of leukemia-free survival (LFS) was 44.2%6 7.4% at 3 years. Patients transplanted during their first
complete remission (CR1) had a lower relapse rate (18.8% versus 37.5%, P 5 .049, with a relative risk
[RR] 5 0.247, P 5 .007), a lower nonrelapse mortality (NRM) rate (16.6% versus 50.0%, P 5 .046, with an
RR5 0.279, P5.024), and better LFS (54.8% versus 12.5%, P5.001, with an RR5 0.315, P5.004) compared
with patients transplanted beyondCR1. This study confirmed that haploidentical/mismatchedHSCT could be
an alternative treatment choice for T-ALL.
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The relative rarity of T cell acute lymphoblastic
leukemia (T-ALL) has made it difficult to describe
clinical outcomes and the factors determining out-
come. Allogeneic hematopoietic stem cell transplanta-
tion (HSCT) remains 1 of the curative therapies
currently available. However, there have been few
studies regarding the efficacy of this treatment. In
the UKALL XII/ECOG 2993 study, Marks et al. [1]
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6/j.bbmt.2011.08.024donor had superior 5-year survival to those without
donors (61% versus 46%, chi-square, P 5 .02) as the
result of less relapse (25% versus 51% at 5 years,
P \ .001). Restrictions based on donor availability
limit the use of HSCT to a small number of patients.
Therefore, HSCT from other donors is an alternative
treatment modality that deserves investigation.
Recently, our institute established a new method
for HLA-mismatched/haploidentical HSCT using
granulocyte-colony stimulating factor (G-CSF)-
primed bone marrow (G-BM) plus G-CSF-mobilized
peripheral blood stem cells (G-PB) without ex vivo
T cell depletion after the patients were treated with
busulfan, cyclophosphamide, cytosine arabinoside,
and methyl CCNU plus antithymocyte globulin. The
results for this novelmethod in acute leukemia, chronic
myeloid leukemia, and myelodysplastic syndrome
patients are promising [2-4]. However, there have
been no reports concerning treatment of subgroups
of T-ALL patients until now. Our current study
describes the outcomes of 72 patients diagnosed with
T-ALL treated uniformly with HSCT from
haploidentical/mismatched donors.
Table 1. Characteristics of Patients with T-ALL Receiving
HLA-Mismatched/Haploidentical HSCT
n 72
Age, median (range) 20 (3-48) years
<35 59
$35 13
Gender
Male 55
Female 17
Disease status at transplantation
CR1 56
CR2 9
REL 7
Diagnostic WBC, median (range) 26 (0.8-553) 109/L
<100 57
100 or more 15
CNS involvement
Yes 12
No 60
Tumor mass
Yes 38
No 34
Time from chemo to CR1, median (range) 30 (8-214) days
#30 40
>30 32
Duration from diagnosis to HSCT,
median (range)
210 (110-2740) days
#210 38
>210 34
HLA-mismatched loci (%)
1 6 (8)
2 25 (35)
3 41 (57)
Donor-recipient gender
Female-male 21
Female-female 9
Male-male 35
Male-female 7
Donor (%)
Mother 28 (39)
Father 21 (29)
Child 2 (3)
Sibling 19 (26)
Uncle or aunt 2 (3)
MNCs, median (range) 7.5 (3.5-12.25) 108/kg
#7.5 36
>7.5 36
CD34+ count, median (range) 1.89 (0.65-5.77) 106/kg
CD3+ count, median (range) 1.54 (0.5-8.25) 108/kg
Follow-up time, median (range) 367 (29-2672) days
Follow-up time in survivors, median (range) 638 (47-2672) days
CNS indicates central nervous system; MNC, mononuclear cell count.
Biol Blood Marrow Transplant 18:716-721, 2012 717Haploidentical Transplants for T-ALLMATERIALS AND METHODS
Patients
Seventy-two consecutive patients who were diag-
nosed with T-ALL and who had received an HLA-
mismatched allogeneic HSCT without in vitro T cell
depletion from January 2004 to March 2011 at the
Peking University Institute of Hematology, People’s
Hospital, were analyzed. The institutional review
board at the Peking University Institute of Hematol-
ogy approved the protocol, and all patients or their
guardians signed consent forms approved by the insti-
tutional review board.
All enrolled patients had immunophenotyping
studies and were designated as T-lineage ALL. This
was based on the detection of intracytoplasmic CD3
in the entire blast cell population by flow cytometry
[5]. Cytogenetic analysis of pretreatment bone marrow
or peripheral blood samples was successfully per-
formed in only 20 patients using standard definitions
[6]; the others were either not attempted or failed, as
indicated in Table 1. Therefore, cytogenetics was not
included in the risk factor analysis.
The enrolled patients all met the following criteria:
no available HLA-identical related or unrelated
donors, sufficient cardiac function, creatinine clear-
ance .70 mL/min, lung diffusion capacity of at least
80%, and transaminases\2 times the upper limit of
normal. Patients were not eligible for HSCT if they
had a Karnofsky performance status of \80 or any
active infections. Seventeen patients had been reported
on in a previous paper [2] and have been further
followed up in this study. Patient characteristics are
summarized in Table 1. Follow-up for all patients
extended through June 15, 2011.
Donor and HLATyping
Family members were assessed for degree of
mismatch. HLA-A and HLA-B typing was performed
by intermediate resolution DNA typing, while HLA-
DRB1 and HLA-C typing was performed using high-
resolution DNA techniques. Each patient received
stem cells from a family member who shared 1 HLA
haplotype with the patient but differed to a variable
degree for the HLA-A, B, and D antigens of the haplo-
type that were not shared. Apart from each donor-
recipient pair, HLA typing was done for parents and
offspring to be strictly analyzed to guarantee a true hap-
loid genetic background.Thedegree ofHLAmismatch
is displayed inTable 1.Nearly three-fourths of the stem
cells (n5 53) came from the donors other than siblings.
Family donors were ranked on the basis of best HLA
match, age (younger preferred), and health status.
Conditioning Regimen
Conditioning therapy consisted of cytarabine
(4 g/m2 per day) intravenously on days 210 to 29;busulfan (3.2 mg/kg per day) intravenously on days
28 to26; cyclophosphamide (1.8 g/m2 per day) intra-
venously on days 25 to 24; Me-CCNU (250 mg/m2)
orally once on day 23; and antithymocyte globulin
(2.5 mg/kg per day; Sang Stat, Lyon, France) intrave-
nously for 4 consecutive days from days 25 to 22.
Collection of Hematopoietic Cells
G-CSF (5 mg/kg per day) was used to mobilize
bone marrow (G-BM) and peripheral blood (G-PB).
Both G-BM (harvested on day 4 after G-CSF) and
G-PB (harvested on day 5 after G-CSF) cells were
harvested. The target mononuclear cell count was
$6  108 per kg recipient patient weight. Fresh and
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stem cells were infused into the recipient on the day
of collection. In instances of ABO major blood group
incompatibility, red cells were removed by density
gradient sedimentation with Hespan according to the
manufacturer’s instructions.
Supportive Care
All patients were nursed in single rooms with
HEPA-filtered air and received prophylactic antibiotics
if their absolute neutrophil count (ANC) was
\1  109 cells/L. Fluconazole was given to all patients
from day25 to day130. Trimethoprim/sulfamethoxa-
zole was administered for prophylaxis against Pneumo-
cystis jirovecii infection. Acyclovir was given as Herpes
prophylaxis from day 1 until day 180. Patients were
monitored weekly for cytomegalovirus infection by
polymerase chain reaction (PCR). Cytomegalovirus-
positive patients were treated with either ganciclovir
or foscarnet. All red blood products were irradiated
(2500 cGy) before infusion.
Graft-versus-Host Disease (GVHD) Prophylaxis
GVHD prophylaxis included 1.25 mg/kg cyclo-
sporin A given from day29 to 6 months posttransplan-
tation. The dose of cyclosporin A was adjusted after
monitoring serum levels to maintain a trough level
between 150 and 250 ng/mL and was tapered from
day 90 such that it was discontinued on day 180. Meth-
otrexate, at a dose of 15 mg/m2, was given on day 1, and
10 mg/m2 was given on days 3, 6, and 11 posttransplan-
tation. Chronic GVHD (cGVHD) was evaluated in pa-
tients surviving more than 100 days with sustained
engraftment. The criteria for grading acute GVHD
(aGVHD)andcGVHDwerepreviouslypublished [7,8].
Engraftment and Rejection
The day of engraftment was defined as the first day
of 3 consecutive posttransplantation days on which the
ANC exceeded 500/mL. Patients who did not achieve
this level of ANC at any time after transplantation
were considered to have primary graft failure. Patients
with initial engraftment who experienced a severely
hypocellular marrow and ANC of \500/mL that
recurred for more than 3 days were considered to
have secondary or late-graft failure. Patients who
survived at least 28 days were considered evaluable
for engraftment.
Relapse and Chimerism Analyses
All patients were scheduled to have marrow
samples examined morphologically and by cytogenetic
and flow cytometric analyses on days 30, 60, 90, and
180 after HSCT and then annually or as clinically
indicated. Minimal residual disease (MRD) was
evaluated by fluorescence in situ hybridization(FISH) and flow cytometry. Moreover, MRD was
monitored by quantitative PCR for the detection of
WT1. Relapse was defined by morphologic evidence
of disease in the peripheral blood, marrow, or extrame-
dullary sites. Patients showing MRD were not classi-
fied as having relapsed.
Chimerism was evaluated on recipient BM cells,
usually on days 30, 180, and 365 after HCT, by cyto-
genetic G-banding or FISH. When the patient and
donor were of the same sex, chimerism was assessed
by using PCR-based analyses of polymorphic minisa-
tellite or microsatellite regions (variable number of
tandem repeats).
Donor Lymphocyte Infusion (DLI)
Modified DLI was administered when patients
without aGVHD showed evidence of recipient chime-
rism or MRD detected by molecular, cytogenetic, or
hematologic methods following a trial immunosup-
pressant withdrawal. The modified DLI regimen
consisted of G-CSF-primed peripheral blood stem
cells instead of harvested nonprimed donor lympho-
cytes and short-term immunosuppressive agents.
Eleven patients were administered prophylactic DLI
because the nonremission status or the second com-
plete remission (CR2) before transplantation implied
a very high risk of leukemia relapse in the case of
GVHD absence [9]. Therapeutic DLI was performed
in 7 patients as a treatment for disease recurrence after
transplantation [10].
Statistical Analysis
Cumulative incidents were estimated for engraft-
ment, GVHD, nonrelapse mortality (NRM), and
relapse to accommodate competing risks. The com-
peting risk for engraftment was death without engraft-
ment; the competing risks for GVHD were death
without GVHD, relapse, and graft rejection; relapse
was a competing risk for NRM; and NRM was a com-
peting risk for relapse. For all of our study population
(with or without DLI), the time to GVHDwas defined
as the time from HSCT to the onset of any grade of
GVHD; aGVHD was censored at day 100 after
HSCT, and cGVHD was censored at last follow-up.
Associations between potential factors and outcome
were evaluated using an add-on package for R statisti-
cal software (Mathsoft, Seattle,WA) that allows for the
estimation of the semiparametric proportional hazards
model for the subdistribution of a competing risk anal-
ysis, as proposed by Scrucca L, et al. [11]. For continu-
ous variables, the median or the criteria value indicated
in the published report (ie, patients older than 35 years
or those with a high white blood cell (WBC) count at
presentation [$100  109 cells/L for T-lineage have
been shown to be high-risk]) [12] was used as the cutoff
point. The probabilities of overall survival (OS) and
leukemia-free survival (LFS) were estimated by the
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for OS and LFS were evaluated in univariate analyses
by the log-rank test, with a P value\.05 considered
statistically significant. In multivariate analysis, all
factors found to influence outcomes in univariate
analysis with a P\ .10 were included into a Cox pro-
portional hazard model using time-dependent vari-
ables. SAS version 8.2 (SAS Institute, Cary, NC) and
S Plus 2000 (Mathsoft, Seattle, WA) were used for
most analyses.RESULTS
Patient Characteristics
T cell disease was more commonly seen in males:
three-quarters of our study population were male, as
indicated in Table 1. The median age at diagnosis was
20 years. There was an association between T cell
disease and a high WBC count, with 35% of our study
population having a WBC count of more than 50 
109 cells/L. Furthermore, 16% of our study population
had central nervous system involvement at diagnosis.
Engraftment
All 72 patients except 1 achieved sustained myeloid
engraftment. At least 2 of 3 methods (HLA-DNA
typing, PCR-DNA fingerprinting, and chromosomal
FISH) were used to confirm 100% donor chimerism
in all of the patients except 1. Themedian time to reach
an absolute neutrophil count above 0.5  109 cells/L
was 13 days (range: 10-30 days). One patient died
from sepsis at day 29 without myeloid engraftment.
Sixty-eight patients had platelet engraftment during
the follow-up period, and the median time to reach
a platelet count above 20  109 cells/L was 16 days
(range: 8-96 days).
GVHD
Seventy-one patients with engraftment survived
at least 28 days and were evaluable for the development
of aGVHD. Eighteen patients had grade II aGVHD,
6 had grade III aGVHD, and 3 had grade IV aGVHD.
The cumulative incidence rates at 100 days post-HCT
of grades II to IV aGVHD and of grades III and
IV aGVHD were 49% 6 12% and 19% 6 12%,
respectively.
Thirty-one patients survived more than 100 days
after transplantation and were evaluated for cGVHD.
Chronic GVHD occurred in 25 patients; 12 developed
limited cGVHD, while 13 developed extensive
cGVHD. The cumulative incidence rate for cGVHD
after 2 years was 41% 6 12%.
Relapse
As of June 15, 2011, 15 patients had recurrent
disease after a median of 120 days (range: 47-282 days),reaching a cumulative incidence of relapse of 23.1%6
5.2% at 2 years. Nine of the 56 patients with CR1, 3 of
the 9 patients with CR2, and 4 of the 7 patients with
nonremission status at transplantation had relapsed
after HSCT.
After relapse, 7 patients received chemotherapy
followed by the infusion of G-PB from the same donor
to treat the relapse. Among these 7 patients with
therapeutic DLI, 3 patients showed no response to
the DLI, and 2 of these 3 patients died at 59 and
130 days after relapse. The other patient survived
with leukemia at 92 dyas after relapse at last follow-
up. Two patients showed a temporary response to
the DLI but then relapsed again and died at 775 and
579 days after relapse. Two patients showed a tempo-
rary response to the DLI and then received a second
transplant; however, they relapsed again and died at
135 and 452 days after relapse. Two patients received
chemotherapy alone and died at 94 and 169 days after
relapse, respectively. One patient received irradiation
therapy alone and died at 112 days after relapse.
Five patients recevied no therapy and died at a median
of 21 days (10-44 days) after relapse.
In a univariate analysis of risk factors for relapse
(Table 2), tumormass at diagnosis and non-CR1 status
at transplantation were associated with higher relapse
rates. Among patients with CR1, CR2, or nonremis-
sion status before HSCT, the 2-year cumulative inci-
dence of relapse was 18.8%, 22.2%, and 57.1%,
respectively (P 5 .044). In the multivariate model, re-
mission status at transplantation was found to be the
only predictor for relapse (P 5 .007; relative risk
[RR], 0.247; 95% confidence interval [CI], 0.089-
0.686; Table 3).LFS and Long-Term Follow-up
At a median follow-up of 12 months (range:
1-89 months), 41 patients were alive, with a median
time of 21 months after transplantation without
disease recurrence. The probalities of OS and LFS
were 45.6% 6 7.5% and 44.3% 6 7.4% at 3 years,
respectively (Figure 1).
As mentioned above, 14 of the 15 relapsed patients
died from recurrent disease. Sixteen patients died from
other causes than relapse, as shown in Table 4. The
most frequent cause of death was infection, specifi-
cally, pneumonia. Severe GVHD was likely the direct
cause of death in 1 patient. The NRM rate at 2 years
was 24.8% 6 5.7%.
As shown in Table 2, patient sex and disease status
before HSCT had effects on LFS. Among patients
with CR1, CR2, or nonremission status before
HSCT, the estimated 3-year probability of LFS was
54.9%, 33.3%, and 0%, respectively. Therewas a trend
that patients who received grafts from 3 locus mism-
ached donors had worse outcomes compared with
Table 2. Univariate Analysis of Transplant Outcomes in 72
Patients with T-ALLTreated with Haploidentical/Mismatched
HSCT
Risk Factor LFS Relapse NRM
HLA nonidentical locus
1-2 n 5 31 52.7% 24.4% 17.6%
3 n 5 41 39.6% 21.9% 35.3%
P .154 .778 .068
Gender
Male n 5 55 51.3% 21.7% 21.8%
Female n 5 17 16.0% 27.1% 53.4%
P .040* .617 .088
Diagnostic WBC
<100 n 5 57 48.9% 23.1% 23.0%
100 or more n 5 15 27.7% 22.7% 46.1%
P .276 .998 .223
CNS involvement
Yes n 5 12 58.3% 33.3% 8.3%
No n 5 60 37.6% 21.0% 33.7%
P .441 .298 .096
Tumor mass
Yes n 5 38 37.7% 33.5% 32.6%
No n 5 34 52.4% 10.9% 24.6%
P .144 .021* .643
Time from chemo to CR1
#30 days n 5 40 48.5% 18.3% 28.4%
>30 days n 5 32 38.0% 29.2% 26.3%
P .124 .197 .705
Disease status before HSCT
CR1 n 5 56 54.8% 18.8% 16.6%
Non-CR1 n 5 16 12.5% 37.5% 50.0%
P .001* .085 .046*
Disease duration before HSCT
#7 months n 5 38 50.9% 23.6% 23.1%
>7 months n 5 34 37.5% 22.6% 33.0%
P .42 .962 .393
Age
<35 years n 5 59 42.6% 26.7% 24.5%
$35 years n 5 13 47.9% 8.5% 43.5%
P .876 .171 .125
Median MNCs, 108/kg
#7.5 n 5 36 40.2% 21.5% 34.2%
>7.5 n 5 36 50.9% 24.0% 22.0%
P .61 .588 .158
*P < 0.05.
Figure 1. LFSof patientswithT-ALL after haploidentical transplantation.
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lower LFS as a result of higher NRM in the former
group, although it did not reach the statistical signifi-
cance. However, the 100-day cumulative incidence of
severe aGVHD occurred almost equally in the
2 groups (20.8% versus 17.2%, P5 .85). In the multi-
variate model, remission status at transplantation was
found to be the only predictor for NRM and LFS
(P 5 .024; RR, 0.279; 95% CI, 0.092-0.847, and
P 5 .004; RR, 0.315; 95% CI, 0.144-0.691, respec-
tively; Table 3).Table 3. Multivariate Analysis of Relapse, NRM, and Survival
Outcome Hazard Ratio (95% CI)* P
Relapse
CR1 versus non-CR1 0.247 (0.089-0.686) .007
NRM
CR1 versus non-CR1 0.279 (0.092-0.847) .024
LFS
CR1 versus non-CR1 0.315 (0.144-0.691) .004
*CI indicates confidence interval.DISCUSSION
In this report, we present a detailed description of
72 patients with T-ALL who were uniformly treated
with haploidentical HSCT. Seventy-one patients
achieved sustained myeloid engraftment. The cumula-
tive incidence rates in this cohort of grades II to IV
aGVHD and severe aGVHD were 49% and 19%,
respectively, which are similar to our previous reports
of 55% and 23%, respectively, among 171 patients
with hematologic malignancies treated using the
same protocol [2]. The 3-year LFS for patients in
CR1 was 54.8%. All of these findings confirm that
our protocol is safe and effective and feasible for
a relatively rare disease such as T-ALL.
The biological characteristics of T-ALL are some-
what different from those of B cell acute lymphoblastic
leukemia (B-ALL) [1,13]. The biologic features of our
study population and their influence on outcome are in
accordance with those of the UKALL XII/ECOG
2993 and GIMEMA 0496 studies (ie, T-ALL occurs
more frequently in males younger than age 30 and is
usually accompanied by a high WBC count and
tumor mass). In this study, univariate analysis showed
an influence on relapse for tumor mass and a sex
influence on LFS (ie, males fared better), and patients
who presented with WBC counts at diagnosis of
more than 100  109 cells/L had slightly inferior
survival rates. In the UKALL XII/ECOG 2993 study,Table 4. Causes of Death
Cause No. Patients
Relapse 14
GVHD 1
Infections 15
Bacteria 2
Fungal 5
Viral 6
Unknown 2
Biol Blood Marrow Transplant 18:716-721, 2012 721Haploidentical Transplants for T-ALLolder patients (.35 years) and females had a poorer
outcomes; in the GIMEMA 0496 study, a higher CR
rate was associated with males, younger ages (\30
years), lower WBC counts (\50  109 cells/L), and
lack of lymphadenopathy [13].
The relapse rate in our study was about 23%,
which is comparable with the 25% result of the Marks
report [1], especially considering that more than one-
fifth of our study population had advanced disease.
However, in patients with nonremission status, post-
transplantation relapse continues to be a prevalent
problem. Fielding et al. [14] showed that the outcome
of relapsing patients was very poor, and that patients
with T cell disease had a 5% 5-year survival rate. In
our report, the NRM was 24.8%, which was compara-
ble to the 22% result of the Marks report, which
included 88 patients who received matched sibling
donor transplantation [1]. Our comparable NRM
with matched sibling donor setting demonstrates the
safety of our protocol.
The estimated probability of OS and LFS were
57% and 55% at 3 years. Marks et al. [1] had reported
an OS of 61% for the 88 patients with T-ALL trans-
planted using HLA-identical sibling donors. The esti-
mated probability of OS for chemotherapy in the
Marks report [1] was 46%. The data from the
LALA-94 trial, which included 212 T-ALL patients
who received chemotherapy alone, showed that the
3-year disease-free survival was 35% [15]. The data
from the GIMEMA ALL 0288 trial, which included
134 T-ALL patients who received chemotherapy
alone, showed that the 8-year disease-free survival
was 24% [16]. The LFS of our study population was
both better than previous reports for patients who
received chemotherapy and equal to the survival
after HLA-identical HSCT. All of these findings
suggest that T-ALL could be cured by haploidentical
transplantation.
This study demonstrates that haploidentical/mis-
matched HSCT provided effective treatment for
patients with T-ALL. The results suggest that haploi-
dentical/mismatched allografting in CR1 can be a via-
ble strategy in this patient subgroup.ACKNOWLEDGMENTS
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